genome editing In this article, Emily Evans, healthcare policy analyst at Hedgeye, considers the potential effects of politics, policy and power on the burgeoning healthcare special-purpose acquisition company (SPAC) universe.
Something is sure to go wrong. Over 400 SPACs have formed and about 100 business combinations have been announced. At least as far as health care goes, excluding biotech and pharma, the quality of the business combinations has thus far been uninspiring. Deerfield’s [DFHT] CareMax/IMC Medical merger and Jaws Acquisition’s [JWS] Cano Health are focused on the very crowded medicare advantage market just as demographic realities require attention to shift toward younger people.